Principal, RiverVest Venture Partners
Pascal Krotee, Ph.D., is a Principal at RiverVest Venture Partners. Pascal focuses on sourcing and conducting due diligence on prospective investments while providing operational support across the firm’s biopharmaceutical and medical device portfolios. She is currently a board member at Biolinq and a stealth RiverVest portfolio company and a board observer at Atalanta Therapeutics. She previously served on the Board of Directors at Bluejay Therapeutics through its acquisition by Mirum Pharmaceuticals in January 2026 and as a board observer at Avalyn Pharma (NASDAQ: AVLN).
Prior to joining RiverVest, Pascal was an investment associate at Kairos Ventures, where she focused on life sciences investments. During her time at Kairos, she sourced new investment opportunities, led due diligence, and served on the boards of several portfolio companies.
Pascal earned a Ph.D. in Molecular Biology from UCLA. Prior to graduate school, she worked as a junior specialist at the Development Biology Center at the University of California, Irvine, where she earned a B.S. in Developmental and Cell Biology with a Minor in Business Management.
Outside of RiverVest, Pascal serves as co-president of San Diego’s Spark Bio, a networking organization for the next generation of life science leaders, and a co-organizer of the San Diego Chapter of Breaking 7%, a networking group for women in VC and business development.
Pascal was named a 2023 recipient of Biocom California’s Life Science Catalyst Award, recognizing her as a top-ten life science trailblazer under the age of 40 in California.